Outside the fiber: Endomysial stromal and capillary pathology in skeletal muscle may impede infusion therapy in infantile-onset Pompe disease

J Neuropathol Exp Neurol. 2023 Mar 20;82(4):345-362. doi: 10.1093/jnen/nlad012.

Abstract

The survival of infantile-onset Pompe disease (IOPD) patients has improved dramatically since the introduction of enzyme replacement therapy (ERT) with a1glucosidase alfa. However, long-term IOPD survivors on ERT demonstrate motor deficits indicating that current therapy cannot completely prevent disease progression in skeletal muscle. We hypothesized that in IOPD, skeletal muscle endomysial stroma and capillaries would show consistent changes that could impede the movement of infused ERT from blood to muscle fibers. We retrospectively examined 9 skeletal muscle biopsies from 6 treated IOPD patients using light and electron microscopy. We found consistent ultrastructural endomysial stromal and capillary changes. The endomysial interstitium was expanded by lysosomal material, glycosomes/glycogen, cellular debris, and organelles, some exocytosed by viable muscle fibers and some released on fiber lysis. Endomysial scavenger cells phagocytosed this material. Mature fibrillary collagen was seen in the endomysium, and both muscle fibers and endomysial capillaries showed basal laminar reduplication and/or expansion. Capillary endothelial cells showed hypertrophy and degeneration, with narrowing of the vascular lumen. Ultrastructurally defined stromal and vascular changes likely constitute obstacles to movement of infused ERT from capillary lumen to muscle fiber sarcolemma, contributing to the incomplete efficacy of infused ERT in skeletal muscle. Our observations can inform approaches to overcoming these barriers to therapy.

Trial registration: ClinicalTrials.gov NCT01665326.

Keywords: Capillary; Endomysium; Glycogen; Muscle; Pompe; Stroma; Ultrastructure.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies
  • Capillaries / pathology
  • Endothelial Cells / pathology
  • Glycogen Storage Disease Type II* / drug therapy
  • Glycogen Storage Disease Type II* / pathology
  • Humans
  • Muscle, Skeletal / pathology
  • Retrospective Studies
  • alpha-Glucosidases / therapeutic use

Substances

  • alpha-Glucosidases
  • Antibodies

Associated data

  • ClinicalTrials.gov/NCT01665326